Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
- Author:
Sang Bong AHN
1
Author Information
- Publication Type:Review
- From:Clinical and Molecular Hepatology 2023;29(Suppl):S150-S156
- CountryRepublic of Korea
- Language:English
- Abstract: Nonalcoholic fatty liver disease (NAFLD) affects approximately 30% of the population worldwide and includes nonalcoholic fatty liver, nonalcoholic steatohepatitis (NASH), and cirrhosis. Since NAFLD-associated diseases begin with steatosis, the early diagnosis of steatosis helps to prevent the progression of NASH and fibrosis. In addition, more convenient and easily diagnosable serum biomarkers are becoming crucial in disease diagnosis. In this report, we summarize the known serum biomarkers for liver steatosis and provide guidance for their application in clinical practice.
